ORGANON & CO (OGN)
US68622V1061 - Common Stock
Organon To Present at the 43rd Annual J.P. Morgan Healthcare Conference
Organon Reports Results for the Third Quarter Ended September 30, 2024
US FDA Accepts Biologics License Application (BLA) for HLX14, Biosimilar Candidate of PROLIA/XGEVA (denosumab)
Organon Completes Acquisition of Dermavant, including Innovative Dermatologic Therapy, VTAMA® (tapinarof) Cream, 1%
The acquisition expands Organon’s dermatology capabilities with a nonbiologic, non-steroidal topical treatment in the U.S.
Want $300 in Dividends Every Month? Invest $20,000 in Each of These 3 Stocks
These dividend stocks all pay yields of around 6% and higher.
YieldBoost Organon From 6.4% To 11.4% Using Options
Organon Larger Than S&P 500 Component Deckers Outdoor
Organon to Report Third Quarter 2024 Results and Host Conference Call on October 31, 2024
Organon Canada Promotes Geneviève Gauthier as Executive Director, Corporate Affairs and Community Engagement and Appoints Jeffrey Malawski as Executive Director, Women's Health and Established Brands
/CNW/ - Organon Canada, a subsidiary of Organon (NYSE: OGN), a global healthcare company with a focus on women's health, today announced updates to its...
Primary Endpoint Met in Phase 3 Comparative Clinical Study of Perjeta® (pertuzumab) Biosimilar Candidate HLX11
Organon Canada and the Alberta Women's Health Foundation unite to raise awareness and advocate for universal access to contraception in Canada
/CNW/ - In recognition of World Contraception Day (WCD) on September 26, Organon Canada, a subsidiary of Organon (NYSE: OGN), a global healthcare company with...
Organon to Acquire Dermavant including its Innovative Dermatologic Therapy, VTAMA® (tapinarof) Cream, 1%
Organon to Acquire Dermavant including its Innovative Dermatologic Therapy, VTAMA® (tapinarof) Cream, 1%
Organon Stock Sees Relative Strength Rating Rise To 91
On Tuesday, Organon[ stock hit an key technical milestone, seeing its Relative Strength Rating jump to 91, up from 88 the day before.
Organon Stock Earns Relative Strength Rating Upgrade; Hits Key Threshold
On Tuesday, generic drug maker Organon stock had its Relative Strength (RS) Rating upgraded to 83, up from 78 a day earlier.
Organon & Lilly Expand Migraine Commercialization Agreement to 11 Additional Markets
Organon Enters Oversold Territory (OGN)
OGN Stock Earnings: Organon Beats EPS, Misses Revenue for Q2 2024
OGN stock results show that Organon beat analyst estimates for earnings per share but missed on revenue for the second quarter of 2024.
Organon Reports Results for the Second Quarter Ended June 30, 2024
First Week of August 16th Options Trading For Organon (OGN)
Organon To Report Second Quarter 2024 Results and Host Conference Call on August 6, 2024
3 High-Yield Dividend ETFs to Buy to Generate Passive Income
These exchange-traded funds should keep the income flowing in regularly.
Value Investing Is Back! 3 Stocks With Strong Fundamentals to Buy Now
Uncover three top value stocks to buy with robust fundamentals for stable long-term growth amid turbulence.
Interesting OGN Put Options For June 21st
3 Stocks With Mouthwatering Dividends You Can Buy Right Now
These stocks offer great dividends and more.